Dyn.
Internet performance company
- Reports this week
- 0
- Active events
- 0
- Connections
- 33
What's happening
Earlier this month
Gone quiet
No new reports in 90+ days-
Dyn announced an offering pursuant to SEC registration, with Morgan Stanley and Raymond James serving as joint book-running managers, and Jones leading the effort.Some support1 report
-
Both Dyn and Viking Therapeutics are noted as competing firms within the clinical-stage biotech sector.Some support1 report
-
Dyne Therapeutics is expanding and strengthening its board, appointing Greene, while John Cox serves as CEO.Some support1 report
-
Dyne announced the development of therapies for DMD and myotonic dystrophy type 1, with John Cox serving as CEO.Some support3 reports1 development inside
-
Dyne received FDA Breakthrough Therapy Designation and submitted revised protocols based on feedback regarding its therapies for DMD and myotonic dystrophy type 1.Speculative1 report
-
JonesTrading initiated coverage with a Buy rating for Dyn on June 26, 2025.Some support2 reports
-
Dyn filed an offering with the SEC on July 3, 2025, with Morgan Stanley and Stifel serving as joint book-running managers.Speculative3 reports1 development inside
-
Dyn secured debt financing from Hercules Capital on July 1, 2025.Speculative1 report
-
Wildon R Farwell joined Satellos Bioscience Inc. as CMO and will advance SAT-3247 in trials.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Dyn this week
News at the entities that move Dyn most-
FDA StructuralNeurogene Inc. developed a gene therapy for Rett syndrome and received FDA agreement for a registrational trial design.Moves Dyn
-
SEC StructuralLaser Photonics Corporation hired Tim Peterman as Chief Financial Officer and engaged CBIZ for financial reporting consulting.Moves Dyn
-
Jefferies Financial Group Mentioned togetherGE Vernova received a 'buy' rating and target price raise from Jefferies, alongside required SEC filings on May 27, 2026.Moves Dyn
-
Viking Therapeutics OperationalMajor pharmaceutical companies, including Viking Therapeutics, Eli Lilly, and Novo Nordisk, are advancing their weight loss drug pipelines.Moves Dyn
-
Jones StructuralThe FBI has launched an investigation into an alleged bribery scheme involving Jones.Moves Dyn
-
board of directors StructuralThe company's board of directors declared a cash dividend on April 11, 2024.Moves Dyn
Connections
The 15 strongest of 33, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
Dyn is subject to formal regulatory review and designation processes by the FDA for its therapeutics.
-
John Cox Structural
John Cox holds the role of President and CEO of Dyn Therapeutics.
-
DMD Structural
Dyn is actively developing therapeutic treatments targeting DMD.
-
SEC Structural
Dyn is subject to SEC regulation, requiring disclosure of transactions.
-
Jason Rhodes Structural
Jason Rhodes serves as a director of Dyn, a formal governance role that binds the individual to the company's operations.
-
Viking Therapeutics Operational
The firms actively compete within the clinical-stage biotech sector.
-
Morgan Stanley Transactional
Morgan Stanley is engaged as a joint book-running manager for Dyn, indicating a specific, time-bound financial service arrangement.
-
Jones Structural
Jones holds the functional role of lead manager for Dyn.
Show all 15 connections
-
board of directors Structural
The board of directors operates as a formal governing body within the structure of Dyn.
-
Jefferies Financial Group Mentioned together
Jefferies Financial Group issued a buy rating on the shares of Dyn.
-
Stifel Transactional
Stifel acted as a joint book-running manager in a financial offering involving Dyn.
-
Nasdaq Shared context
Dyn operates as a company listed and trading on the Nasdaq stock exchange.
-
Raymond James Operational
Raymond James is serving as a joint book-running manager for Dyn.
-
Donald Trump Shared context
Dyn is explicitly noted as not being affected by the tariffs associated with Donald Trump's policies.
-
Jones Mentioned together
No evidence linking Dyn and Jones was found in the provided snapshots.
History
Events by the month they beganJune 2026
9 events- Trump-era tariffs are reportedly benefiting certain AI stocks, coinciding with the spin-off of Millrose Properties, Inc. from Lennar Corporation.
- Both Dyn and Viking Therapeutics are noted as competing firms within the clinical-stage biotech sector.
- Dyne Therapeutics is expanding and strengthening its board, appointing Greene, while John Cox serves as CEO.
- Dyne announced the development of therapies for DMD and myotonic dystrophy type 1, with John Cox serving as CEO.
- Dyne received FDA Breakthrough Therapy Designation and submitted revised protocols based on feedback regarding its therapies for DMD and myotonic dystrophy type 1.
- JonesTrading initiated coverage with a Buy rating for Dyn on June 26, 2025.
- Dyn filed an offering with the SEC on July 3, 2025, with Morgan Stanley and Stifel serving as joint book-running managers.
- Dyn secured debt financing from Hercules Capital on July 1, 2025.
- Wildon R Farwell joined Satellos Bioscience Inc. as CMO and will advance SAT-3247 in trials.